Shots:

• The P-III OA (A4091056) study involves evaluation of Tanezumab (2.5- 2.5/5 mg SC) vs PBO in 698 patients in ratio (1:1:1) with OA of the knee or hip for 16wks.
• P-III OA (A4091056) study results: WOMAC Pain (-3.2- -3.4 vs -2.6); Reduction from baseline ≥30/50/70/90% (68.0% -54.5% -34.6%- 14.7%: 70.4%- 57.1%- 36.5%- 14.2% vs 54.5%- 37.9%- 25.0%- 9.5%); WOMAC physical function (-3.2- -3.5 vs -2.6); PGA-OA (-0.87- -0.90 vs -0.65); RPOA Type 1/2 (1.3%- 0.9%: 0.4%- 0%)
• Tanezumab is a mAb and is jointly co-developed & co-commercialized by Pfizer and Lilly in response to 2013 deal. Lilly to present the above results at ACR/ARHP18

/ article | Ref:  Pfizer | Image: NJ